Innate and early B cell responses to V. cholerae
对霍乱弧菌的先天和早期 B 细胞反应
基本信息
- 批准号:8630383
- 负责人:
- 金额:$ 82.07万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-12-01 至 2018-11-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAffinityAntibodiesAntigensB-Cell ActivationB-LymphocytesBangladeshBiopsyBlood CirculationCellsCharacteristicsCholeraCholera VaccineClinical ResearchCloningCollaborationsDataDendritic CellsDeveloping CountriesDevelopmentDiagnosticDiseaseEarthquakesEpidemicEvaluationEventFosteringGeneral HospitalsGenerationsGenesHaitiHomingHumanImmuneImmune responseImmunityImmunoglobulin GenesImmunoglobulin IsotypesImmunoglobulin Light Chain GenesImmunoglobulin-Secreting CellsImmunologic MemoryImmunologicsIndividualInfectionInstitutesIntestinesKineticsLifeMassachusettsMeasuresMemory B-LymphocyteMucosal Immune ResponsesMucous MembraneOralOutcomePathogenesisPathway interactionsPatientsPlasma CellsPlasmablastPoliciesPopulationPrevention strategyProductionResearchSignal PathwaySomatic MutationSorting - Cell MovementSpecificitySurfaceSystems BiologyTherapeuticTissuesUniversitiesVaccinationVaccinesVibrio choleraeWorkbactericidehuman monoclonal antibodiesimprovedinnovationinternational centerkillingslong term memorymedical schoolsnovelnovel strategiesoral vaccinepathogenperipheral bloodpublic health relevanceresponsetoolvolunteer
项目摘要
PROJECT SUMMARY
Cholera remains an important cause of diarrheal illness, as evidenced by its recent emergence in post-
earthquake Haiti. Scientific and policy leaders are increasingly calling for the use of preventive strategies such
as vaccination for diarrheal diseases like cholera, but current cholera vaccines suffer from immunologic
limitations. Most importantly, oral cholera vaccines elicit protection of short duration -- in contrast to natural
infection with V. cholerae, which induces long-lasting immunity.
In the research proposed here, we seek to identify the earliest differences in the innate and B cell
immune responses after natural infection versus cholera vaccination. We also aim to identify which of these
early differences are most critical for the subsequent development of long term immunologic memory.
Understanding these early differences may explain why only natural infection with V. cholerae gives rise to
long term memory B cell responses which are important for protection against cholera.
Because V. cholerae is a human-restricted pathogen, clinical studies are essential to address this
question. We propose to draw upon existing collaborations between the Massachusetts General
Hospital/Harvard Medical School (MGH/HMS), the International Centre for Diarrhoeal Disease Research,
Bangladesh (ICDDR,B), the Emory Vaccine Center, and the Broad Institute of MIT/Harvard University to
address this question in humans. Specifically, we will compare the activation of innate immune responses in
mucosal tissue after cholera infection versus vaccination, and we will evaluate which of these differences
correlate with long term memory B cell responses in cholera patients. We will also compare antibody secreting
cell (ASC) responses in patients and vaccinees. Cloning of immunoglobulin genes and the production of these
cloned antibodies from individual ASCs may improve our understanding of differences in the B cell responses
between cholera patients and vaccine recipients, and the resulting antibodies may also provide tools with
diagnostic and therapeutic potential. These studies will improve our understanding of the mechanisms through
which innate immune responses at the mucosal surface foster long-lasting immunity and may point to novel
strategies for improving upon current cholera vaccines.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JASON B HARRIS其他文献
JASON B HARRIS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JASON B HARRIS', 18)}}的其他基金
Single dose azithromycin to prevent cholera in children
单剂量阿奇霉素预防儿童霍乱
- 批准号:
10632107 - 财政年份:2021
- 资助金额:
$ 82.07万 - 项目类别:
Single dose azithromycin to prevent cholera in children
单剂量阿奇霉素预防儿童霍乱
- 批准号:
10462780 - 财政年份:2021
- 资助金额:
$ 82.07万 - 项目类别:
Single dose azithromycin to prevent cholera in children
单剂量阿奇霉素预防儿童霍乱
- 批准号:
10297046 - 财政年份:2021
- 资助金额:
$ 82.07万 - 项目类别:
Innate and early B cell responses to V. cholerae
对霍乱弧菌的先天和早期 B 细胞反应
- 批准号:
9185932 - 财政年份:2013
- 资助金额:
$ 82.07万 - 项目类别:
Immune Responses to Vibrio cholerae infection and vaccination in Haiti
海地霍乱弧菌感染和疫苗接种的免疫反应
- 批准号:
8554355 - 财政年份:2012
- 资助金额:
$ 82.07万 - 项目类别:
Immune Responses to Vibrio cholerae infection and vaccination in Haiti
海地霍乱弧菌感染和疫苗接种的免疫反应
- 批准号:
8706677 - 财政年份:2012
- 资助金额:
$ 82.07万 - 项目类别:
Immune Responses to Vibrio cholerae infection and vaccination in Haiti
海地霍乱弧菌感染和疫苗接种的免疫反应
- 批准号:
8896410 - 财政年份:2012
- 资助金额:
$ 82.07万 - 项目类别:
Immune Responses to Vibrio cholerae infection and vaccination in Haiti
海地霍乱弧菌感染和疫苗接种的免疫反应
- 批准号:
8437751 - 财政年份:2012
- 资助金额:
$ 82.07万 - 项目类别:
Development of a small molecule screen for PhoP regulon inhibitors in Salmonella
沙门氏菌 PhoP 调节子抑制剂小分子筛选的开发
- 批准号:
7290659 - 财政年份:2007
- 资助金额:
$ 82.07万 - 项目类别:
Development of a small molecule screen for PhoP regulon inhibitors in Salmonella
沙门氏菌 PhoP 调节子抑制剂小分子筛选的开发
- 批准号:
7678707 - 财政年份:2007
- 资助金额:
$ 82.07万 - 项目类别:
相似海外基金
Multidimensional development of high-affinity anti-glycan antibodies to fight deadly bacterial infections
多维开发高亲和力抗聚糖抗体以对抗致命细菌感染
- 批准号:
10549640 - 财政年份:2023
- 资助金额:
$ 82.07万 - 项目类别:
Computational modelling and simulation of antibodies to enhance binding affinity of a potential Burkholderia pseudomallei therapeutic
抗体的计算模型和模拟,以增强潜在的鼻疽伯克霍尔德氏菌治疗剂的结合亲和力
- 批准号:
2750554 - 财政年份:2021
- 资助金额:
$ 82.07万 - 项目类别:
Studentship
Affinity Biosensors for COVID-19 Antibodies
适用于 COVID-19 抗体的亲和生物传感器
- 批准号:
61319 - 财政年份:2020
- 资助金额:
$ 82.07万 - 项目类别:
Feasibility Studies
Directed Evolution of HIV Broadly Neutralizing Antibodies Using a Novel CRISPR-Engineered B cell in Vitro Affinity Maturation Platform
使用新型 CRISPR 工程 B 细胞在体外亲和力成熟平台定向进化 HIV 广泛中和抗体
- 批准号:
10013588 - 财政年份:2020
- 资助金额:
$ 82.07万 - 项目类别:
Affinity maturation and property changes of single-domain antibodies through repeated immunizations.
通过重复免疫,单域抗体的亲和力成熟和性质变化。
- 批准号:
20K07009 - 财政年份:2020
- 资助金额:
$ 82.07万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Rapid structure-based software to enhance antibody affinity and developability for high-throughput screening: Aiming toward total in silico design of antibodies
基于快速结构的软件可增强抗体亲和力和高通量筛选的可开发性:旨在实现抗体的全面计算机设计
- 批准号:
10603473 - 财政年份:2020
- 资助金额:
$ 82.07万 - 项目类别:
IN SILICO DESIGN OF HIGH-AFFINITY RECOMBINANT ANTIBODIES
高亲和力重组抗体的计算机模拟设计
- 批准号:
2342674 - 财政年份:2020
- 资助金额:
$ 82.07万 - 项目类别:
Studentship
Strategies for generating high affinity antibodies against Gram negative bacteria
产生针对革兰氏阴性菌的高亲和力抗体的策略
- 批准号:
10117194 - 财政年份:2020
- 资助金额:
$ 82.07万 - 项目类别:
Directed Evolution of HIV Broadly Neutralizing Antibodies Using a Novel CRISPR-Engineered B cell in Vitro Affinity Maturation Platform
使用新型 CRISPR 工程 B 细胞在体外亲和力成熟平台定向进化 HIV 广泛中和抗体
- 批准号:
10115604 - 财政年份:2020
- 资助金额:
$ 82.07万 - 项目类别:
Interdisciplinary protein engineering approach to design high affinity antibodies for flaviviruses
跨学科蛋白质工程方法设计黄病毒高亲和力抗体
- 批准号:
10294224 - 财政年份:2018
- 资助金额:
$ 82.07万 - 项目类别:














{{item.name}}会员




